These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31641413)

  • 21. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
    Feldman SR; Werner CP; Alió Saenz AB
    J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
    Guenther LC; Poulin YP; Pariser DM
    Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel.
    Bershad S; Kranjac Singer G; Parente JE; Tan MH; Sherer DW; Persaud AN; Lebwohl M
    Arch Dermatol; 2002 Apr; 138(4):481-9. PubMed ID: 11939810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
    Thiboutot D; Arsonnaud S; Soto P
    J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous determination of tazarotene and its active metabolite tazarotenic acid in minipig plasma by LC-MS/MS and its application in pharmacokinetic study after topical administration of tazarotene gel.
    Tong Y; Pan H; Sun C; Xin X; Ding L; Ma P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 978-979():173-8. PubMed ID: 25550192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Halobetasol Propionate Lotion, 0.05% Provides Superior Hydration Compared to Halobetasol Propionate Cream, 0.05% in a Double-Blinded Study of Occlusivity and Hydration.
    Grove G; Zerweck C; Houser T; Andrasfay A; Gauthier B; Holland C; Piacquadio D
    J Drugs Dermatol; 2017 Feb; 16(2):140-144. PubMed ID: 28300856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Del Rosso J; Draelos Z; Leyden J; Shalita A; Glaser DA; Grimes P; Webster G; Barnett P; Le Gall N
    J Drugs Dermatol; 2010 May; 9(5):549-58. PubMed ID: 20480800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
    J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females.
    Harper JC; Baldwin H; Stein Gold L; Guenin E
    J Drugs Dermatol; 2019 Nov; 18(11):1147-1154. PubMed ID: 31741360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition and biotransformation of the acetylenic retinoid tazarotene in humans.
    Attar M; Yu D; Ni J; Yu Z; Ling KH; Tang-Liu DD
    J Pharm Sci; 2005 Oct; 94(10):2246-55. PubMed ID: 16136553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.
    Bialer M; Shekh-Ahmad T; Braun TL; Halvorsen MB
    Epilepsia; 2013 Aug; 54(8):1444-52. PubMed ID: 23692553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Pharmacokinetics of Once-Daily Dapsone Gel, 7.5% in Patients With Moderate Acne Vulgaris.
    Jarratt MT; Jones TM; Chang-Lin JE; Tong W; Berk DR; Lin V; Kaoukhov A
    J Drugs Dermatol; 2016 Oct; 15(10):1250-1259. PubMed ID: 27741344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris.
    Zouboulis CC; Derumeaux L; Decroix J; Maciejewska-Udziela B; Cambazard F; Stuhlert A
    Br J Dermatol; 2000 Sep; 143(3):498-505. PubMed ID: 10971320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.
    Kircik LH; Papp KA; Stein Gold L; Harris S; Pharm TL; Pillai R
    J Drugs Dermatol; 2019 Mar; 18(3):279-284.. PubMed ID: 30909333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate and Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability.
    Stein Gold L; Pariser DM; Guenin E
    J Drugs Dermatol; 2019 Dec; 18(12):1218-1225. PubMed ID: 31860209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.
    Shalita AR; Chalker DK; Griffith RF; Herbert AA; Hickman JG; Maloney JM; Miller BH; Tschen EH; Chandraratna RA; Gibson JR; Lew-Kaya DA; Lue JC; Sefton J
    Cutis; 1999 Jun; 63(6):349-54. PubMed ID: 10388959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.
    Tanghetti E; Abramovits W; Solomon B; Loven K; Shalita A
    J Drugs Dermatol; 2006 Mar; 5(3):256-61. PubMed ID: 16573259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population.
    Han G; Armstrong AW; Desai SR; Guenin E
    J Drugs Dermatol; 2019 Sep; 18(9):910-916. PubMed ID: 31524347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
    Leyden J; Thiboutot DM; Shalita AR; Webster G; Washenik K; Strober BE; Shupack J
    Arch Dermatol; 2006 May; 142(5):605-12. PubMed ID: 16702498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.
    Kircik LH; Baldwin H; Lain E; Guenin E; Harris S; Bhatt V
    J Drugs Dermatol; 2019 Feb; 18(2):178-188. PubMed ID: 30811141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.